Airtree recently invested in an early stage biologics company. Currently in stealth, they exist to make biologics radically cheaper, so modern medicine reaches the people today's industry prices out, across both human and animal health. 

The Company

Discovery got cheap; manufacturing didn't, and the cost of making antibodies is now what keeps them from patients. That's the constraint we exist to break. We're building factories that deliver a 20–50x cost reduction at scale: more than 10 tonnes of drug substance a year, at under $10 a gram. Think of it as a foundry, a standardised platform that molecules adapt to, rather than a contract manufacturer running a bespoke process per client.

Our founding team has done a version of this before and we're building this company on the same engineering playbook, and hiring the people who'll make it real. We're hiring a research associate to run our purification work day to day, to a very high standard.